Annals of Medicine (Jan 2021)

A randomized, active-controlled, multicentre clinical trial to evaluate the efficacy and safety of oral sitafloxacin versus levofloxacin in Chinese adults with acute uncomplicated or complicated urinary tract infection

  • Ying Li,
  • Yousheng Yin,
  • Xiaomei Peng,
  • Hongguang Zheng,
  • Fajun Fu,
  • Zhenxiang Liu,
  • Xiongfei Wu,
  • Xiaoyan Wu,
  • Song Zheng,
  • Nan Chen,
  • Leye He,
  • Laicheng Ren,
  • Zhaohui Ni,
  • Detian Li,
  • Peiyu Liang,
  • Xiaoju Lv,
  • Yingyuan Zhang

DOI
https://doi.org/10.1080/07853890.2020.1861322
Journal volume & issue
Vol. 53, no. 1
pp. 217 – 226

Abstract

Read online

AbstractPurpose To evaluate the efficacy and safety of oral sitafloxacin versus levofloxacin in Chinese adults with acute uncomplicated urinary tract infection (UTI) or complicated UTI.Methods In this randomized, active-controlled clinical trial, the patients with acute uncomplicated UTI were randomized to receive sitafloxacin 100-mg once-daily (qd) or levofloxacin 500-mg qd orally for 3–5 days. The patients with complicated UTI were randomized to receive sitafloxacin 100-mg twice daily or levofloxacin 500-mg qd orally for 10–14 days. The primary endpoint was the clinical efficacy at test-of-cure (TOC) visit.Results At TOC visit, the clinical cure rate was 89.2% (58/65) in sitafloxacin group and 97.1% (68/70) in levofloxacin group for the patients with acute uncomplicated UTI corresponding to the bacterial eradication rate of 97.1% (34/35) and 97.6% (41/42) (all p > .05), respectively. For the patients with complicated UTI, the clinical cure rate was 81.8% (27/33) in sitafloxacin group and 76.9% (20/26) in levofloxacin group corresponding to the bacterial eradication rate of 93.3% (14/15) and 63.6% (7/11) (all p > .05), respectively. Sitafloxacin and levofloxacin showed similar incidence of drug-related adverse events.Conclusions Oral sitafloxacin is as effective and safe as levofloxacin in treating acute uncomplicated and complicated UTI.KEY MESSAGE:Oral sitafloxacin showed similar clinical cure rate and bacterial eradication rate as levofloxacin for treatment of complicated and uncomplicated urinary tract infections (UTIs) in a randomized, active-controlled, multicentre clinical trial.Oral sitafloxacin is safe and well-tolerated in treating acute uncomplicated and complicated UTIs in Chinese adults.Sitafloxacin is a promising alternative treatment option for UTIs in adults.

Keywords